For instance, in a stem‐cell‐based transgenic model of multiple myeloma, the loss of p53 accelerated the appearance of disease by allowing the MafB oncogene to drive a much more efficient malignant reprogramming (Vicente‐Duenas et al, 2012b,c). This evidence concerns the gene TP53 and plasma cell myeloma.